.Charles Baum, M.D., Ph.D., who managed Mirati Rehabs’ $ 5.8 billion purchase to Bristol Myers Squibb in 2013, is taking the reins of young biotech Terremoto Biosciences.Baum’s “considerable knowledge in medicine growth, and tried and tested record earlier high-impact medications, are going to contribute,” outbound CEO Peter Thompson, M.D., pointed out in a July 25 launch. Thompson will certainly maintain his seat as panel chairperson..Baum, a trained physician-scientist, was the owner, president and chief executive officer of oncology-focused Mirati. Prior to that, he helped cultivate cancer medicines at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Now, Baum will certainly act as chief executive officer at Terremoto, a provider developing small molecules to target disease-causing healthy proteins– like those found in malignant cyst tissues– using covalent connections. Existing therapies that make use of covalent connections predominantly target the amino acid cysteine. Having said that, of the 20 amino acids that compose proteins, cysteine is the minimum popular.
Terremoto is actually as an alternative targeting among the important amino acids, amino acid lysine, which is located in mostly all proteins.Through targeting lysine and also various other amino acids, Terremoto hopes to deal with earlier undruggable diseases and also make first-in-class medications..The biotech, based in South San Francisco, increased $75 thousand in set A backing in 2022. A little bit of more than a year eventually, the biotech more than doubled that number in a $175 million set B.